Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study

1. González-Calle, V.
2. Rodríguez-Otero, P.
3. Sureda, A.
4. de Arriba, F.
5. Reinoso, M.
6. Ribas, P.
7. González-Rodríguez, A.P.
8. González, Y.
9. Oriol, A.
10. Martínez-López, J.
11. González, M.S.
12. Hernández, M.T.
13. Sirvent, M.
14. Cedena, T.
15. Puig, N.
16. Paiva, B.
17. Bladé, J.
18. Lahuerta, J.J.
19. San-Miguel, J.F.
20. Mateos, M.-V.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.3324/HAEMATOL.2023.284089 GOOGLE SCHOLAR lock_openOpen access editor